Safety Shot Inc. Soars 35% Amid FDA Scrutiny and Strategic Financing Moves

Introduction

SAFETY SHOT INC (NASDAQ: SHOT) is a Jupiter, Florida–based wellness and dietary supplement company founded in 2018. Trading under the ticker “SHOT,” the firm develops and markets Sure Shot (formerly Safety Shot until Q4 2024), a patented beverage blend designed to accelerate alcohol metabolism and reduce blood alcohol content (BAC) within minutes. As of July 21, 2025, SHOT shares last traded at $0.6835, up 35.35% on a volume of 5.25 million.

Corporate Structure and Workforce

Safety Shot operates with a team of eight employees under the leadership of CEO Jarrett Boon. The company's small size is utilized to expedite product development and market launches. In Q2 2025, one board member, Dr. Glynn Wilson, resigned, reflecting changes in corporate governance as Safety Shot transitions to public company compliance.

Alcohol recovery by Sérgio Alves Santos

Developments and News

Since its Q4 2023 launch and subsequent rebranding to Sure Shot in Q4 2024, the company has pursued clinical validation and strategic financing. Significant developments include:

• March 4, 2025: Publication in the Journal of Nutrition and Dietary Supplements confirmed in a double-blind, placebo-controlled human trial that Sure Shot® significantly lowers BAC and mitigates hangover symptoms (p < 0.05).
• June 12, 2025: The Annual Shareholders’ Meeting was convened to vote on proposals including a potential reverse stock split (1-for-5 to 1-for-35 ratio) and share issuance tied to the Yerbaé Brands acquisition.
• June 16, 2025: Issuance of 7,275,915 common shares to Silverback Capital Corp. settled $1.46 million in liabilities under a structured settlement program.
• June 18, 2025: Entered a Securities Purchase Agreement issuing 1,157,407 shares at $0.216 each, raising $250,000 to manage financial obligations.
• July 9, 15 & 17, 2025: Filed Forms 8-K (Items 1.01, 3.01, 9.01) reporting material events and corporate matters.
• July 2025: Reports indicated that the FDA has opened an investigation into Safety Shot’s marketing claims and manufacturing practices.

Financial and Strategic Analysis

Safety Shot's market capitalization stands near $75 million, with year-to-date share performance reflecting a slight decline. The company operates at a net loss (TTM EPS –$0.69) and exhibits a high debt-to-equity ratio. Recent equity issuances have bolstered working capital but have also caused dilution for existing shareholders. Technical sentiment remains cautious, with TipRanks rating SHOT as Neutral, citing poor valuation metrics but potential upside from the pending acquisition of Yerbaé, expected to add approximately $12 million in annual revenue once completed. Management’s strategy includes a reverse stock split to restore compliance with minimum bid-price standards and improve market liquidity.

Market Position and Industry Context

Sure Shot operates in the “alcohol recovery” segment alongside products such as The Plug and Morning Recovery. Its patented formula along with peer-reviewed clinical data differentiate it from competitors by claiming measurable BAC reductions within 30 minutes. The company utilizes direct-to-consumer e-commerce platforms and selected grocery chains for distribution. Regulatory scrutiny from the FDA poses challenges and opportunities for compliance and product validation. Strategic partnerships, including collaborations with influencers, aim to improve brand visibility within nightlife and wellness communities.

tl;dr

• SHOT stock increased 35.35% to $0.6835 on July 21, 2025, with a trading volume of 5.25 million shares.
• On June 18, 2025, the company raised $250,000 through a securities purchase agreement; on June 16, 7.28 million shares settled $1.46 million of liabilities.
• Shareholders approved potential reverse stock split (1 for 5 to 1 for 35) and changes to the equity plan on June 12, 2025.
• Peer-reviewed trial (March 4, 2025) demonstrated rapid BAC reduction and alleviation of hangover symptoms.
• An FDA investigation is underway into marketing claims and manufacturing practices.
• Future outlook depends on reverse split approval, successful integration of Yerbaé, and regulatory outcomes.